Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

TEH-TUBE

Financiado

Cerrado

Tissue engineering of the right heart outflow tract by a biofunctionalized biore...

Tissue engineering of the right heart outflow tract by a biofunctionalized bioresorbable polymeric valved tube Approximately 42% of infants’ mortality in the world is related to congenital heart defects (prevalence: 8-12/1000 births). Over 1/3 require the reconstruction of the right ventricular outflow tract (RVOT) by surgical procedures w... ver más

31/12/2017

ASSISTANCE PUBLIQU...

6M€

Presupuesto del proyecto: 6M€

Líder del proyecto

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 8 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2017-12-31 No tenemos la información de la convocatoria

0% 78% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

8 Participantes

ASSISTANCE PUBLIQUE HOPITAUX...

0.00€ | Lider

HEREON

N.D. | Participante

RESCOLL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

IMAVALVE Intelligent materials for in situ heart Valve tissue enginee... 7M€ Cerrado

MAT2008-06887-C03-01 SUPERFICIES POLIMERICAS BIOFUNCIONALIZADAS PARA REGENERACION... 121K€ Cerrado

PRE2019-088735 BIOINGENIERIA DE CONSTRUCTOS BASADOS EN BIOMATERIALES PARA L... 98K€ Cerrado

REBORN Full human based multi scale constructs with jammed regenera... 2M€ Cerrado

Heartbeat 3D-assembly of interactive microgels to grow in vitro vascul... 3M€ Cerrado

BIOMITRAL Engineering the mitral valve bioinspired control of structu... 2M€ Cerrado

Líder del proyecto

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 6M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Approximately 42% of infants’ mortality in the world is related to congenital heart defects (prevalence: 8-12/1000 births). Over 1/3 require the reconstruction of the right ventricular outflow tract (RVOT) by surgical procedures which currently use inert materials without any growth potential. Consequently, multiple reoperations are often required, with their attendant high risk of mortality and morbidity. The TEH-TUBE project will address these limitations by creating a novel bioabsorbable biomaterial using a polymeric valved tube either seeded with autologous adipose tissue derived stem cells (ADSC) or functionalized by a peptidic sequence triggering homing of the host cells onto the scaffold to make it a living self-populated structure. During the project we will: • Compare a number of polymers, including but not limited to polydioxanone, polyhydroxyalkanoate, and poly-ester-urethane-ureas, processed by electrospinning to generate a competent valved tube • Compare, in the selected polymer, different methods of functionalisation using in vitro mechanical and biological tests as well as in vivo animal experiments (primarily rats) • Validate the ultimate combination (polymer + functionalisation technique) in a clinically relevant large animal model (in this case, the growing lamb to specifically assess the regenerative and growth potential of the composite construct) This stepwise approach will be conducted within a tightly controlled regulatory framework to ensure that the final product meets the current ATMP requirements for phase I/II clinical studies and, if successful, ultimate commercialization. Our TEH-TUBE project aims at developing an innovative biomaterial for the treatment of congenital heart abnormalities in children and young adults. By creating a material whose growth will keep pace with that of the patient, this product, geared to become an ATMP, should decrease the risk of reoperative surgeries, improve the quality of life and ultimately have a positive impact on healthcare costs.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores